Mortality and morbidity in transsexual subjects treated with cross-sex hormones.

OBJECTIVE: The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross-sex hormone treatment. DESIGN: A retrospective, descriptive study in a university teaching hospital. SUBJECTS: Eight hundred and sixteen male-to-female (M-->F) and 293 female-to-male (F-->M) transsexuals. INTERVENTIONS: Subjects had been treated with cross-sex hormones for a total of 10,152 patient-years. OUTCOME MEASURES: Standardized mortality and incidence ratios were calculated from the general Dutch population (age- and gender-adjusted) and were also compared to side effects of cross-sex hormones in transsexuals reported in the literature. RESULTS: In both the M-->F and F-->M transsexuals, total mortality was not higher than in the general population and, largely, the observed mortality could not be related to hormone treatment. Venous thromboembolism was the major complication in M-->F transsexuals treated with oral oestrogens and anti-androgens, but fewer cases were observed since the introduction of transdermal oestradiol in the treatment of transsexuals over 40 years of age. No cases of breast carcinoma but one case of prostatic carcinoma were encountered in our population. No serious morbidity was observed which could be related to androgen treatment in the F-->M transsexuals. CONCLUSION: Mortality in male-to-female and female-to-male transsexuals is not increased during cross-sex hormone treatment. Transdermal oestradiol administration is recommended in male-to-female transsexuals, particularly in the population over 40 years in whom a high incidence of venous thromboembolism was observed with oral oestrogens. It seems that in view of the deep psychological needs of transsexuals to undergo sex reassignment, our treatment schedule of cross-sex hormone administration is acceptably safe.

Long-term testosterone administration increases visceral fat in female to male transsexuals.

The amount of intraabdominal (visceral) fat is an important determinant of disturbances in lipid and glucose metabolism. Cross-sectional studies in women have found associations between high androgen levels and visceral fat accumulation. The causal relation between these phenomena is unknown. We, therefore, studied prospectively the effect of testosterone administration on body fat distribution in 10 young, nonobese, female to male transsexuals undergoing sex reassignment. Before, after 1 yr, and after 3 yr of testosterone administration, magnetic resonance images were obtained at the level of the abdomen, hip, and thigh to quantify both sc and visceral fat depots. After 1 yr of testosterone administration, sc fat depots at all levels showed significant reductions compared to baseline measurements. The mean visceral fat area did not change significantly, but subjects who gained weight in the first year after testosterone administration showed an increase in visceral fat. After 3 yr of testosterone administration, sc fat depots were no longer significantly lower compared to pretreatment measurements, but the mean visceral fat depot had increased significantly by 13 cm2 (95% confidence interval, 4-22 cm2), a relative increase of 47% (95% confidence interval, 8-91%) from baseline. The increase in visceral fat was most pronounced in those subjects who had gained weight. We conclude that long term testosterone administration in young, nonobese, female subjects increases the amount of visceral fat. In addition, an increase in weight in this hyperandrogenic state leads to a preferential storage of fat in the visceral depot.

An epidemiological and demographic study of transsexuals in The Netherlands.

This is an epidemiological and demographic study of 1285 transsexuals in the Netherlands. The data were collected from 1975 to the end of 1992. Over 95% of the Dutch transsexuals have been treated at the study center. Between 1975 and 1984 the annual number of female-to-male transsexuals increased, stabilizing thereafter. In the male-to-female transsexuals this trend continued up to 1989, declining slightly thereafter. Over the last 5 years on average 50 (range 38-60) male-to-female transsexuals and 21 (range 14-25) female-to-male transsexuals received surgical and/or hormonal treatment yearly. The sex ratio remained stable over this period: 3 male vs. 1 female subject. The calculated prevalence of transsexualism in The Netherlands is 1:11,900 males and 1:30,400 females. Transsexuals live predominantly in urbanized areas, but those living in nonurbanized areas show an even distribution over the country. The majority of female-to-male transsexuals apply for reassignment between the ages of 20-25, seldom in middle ages. The majority of male-to-female transsexuals do so between the ages of 25-30 and middle-aged subjects are not rare. Between 77-80% of both categories receive surgical and/or hormonal treatment. Five male-to-female transsexuals regretted sex reassignment.

Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol.

We studied prospectively the effect of exogenous testosterone (testosterone undecanoate [TU] 160 mg/d orally) on lipoprotein profiles in eight hypogonadal males and 10 females (female-to-male transsexuals). Testosterone administration to androgen-deficient men and to eugonadal women produced similar serum levels of testosterone (7.67 +/- 5.47 nmol/L v 8.45 +/- 3.81 nmol/L) and 5 alpha-dihydrotestosterone (DHT) (3.27 +/- 3.52 nmol/L v 3.97 +/- 2.35 nmol/L) in the two groups, while serum estradiol levels were three to four times higher in the females (90 +/- 24 pmol/Lv 376 +/- 315 pmol/L). After testosterone treatment serum high-density lipoprotein (HDL) cholesterol levels decreased from 1.41 +/- 0.27 mmol/L to 1.27 +/- 0.22 mmol/L after 3 months and 1.17 +/- 0.23 mmol/L after 6 months (P < .01) in female-to-male transsexuals and from 1.31 +/- 0.39 mmol/L to 1.09 +/- 0.31 mmol/L after 3 months and 1.10 +/- 0.32 mmol/L (P < .05) after 6 months in hypogonadal males. In particular, serum HDL2 cholesterol levels decreased from 0.71 +/- 0.44 mmol/L to 0.45 +/- 0.20 mmol/L after 3 months and 0.49 +/- 0.39 mmol/L after 6 months (P < .01) in female-to-male transsexuals and from 0.52 +/- 0.12 mmol/L to 0.38 +/- 0.18 mmol/L after 3 months and 0.34 +/- 0.19 mmol/L after 6 months (P < .05) in hypogonadal males. Serum apolipoprotein (apo) A1 levels decreased concomitantly. In both sexes, serum levels of HDL cholesterol and HDL2 cholesterol decreased by approximately 15% and 35%, respectively, whereas serum levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, apo A2, and apo B were not affected.(ABSTRACT TRUNCATED AT 250 WORDS)

Phalloplasty in female-to-male transsexuals: what do our patients ask for?

Although the surgical goals of phalloplasty in female-to-male transsexuals have repeatedly been described, the requests by the patients themselves have never been assessed and evaluated properly. To obtain information on their desiderata in this matter a questionnaire was sent to 200 subjects. The answers in the 150 returned questionnaires made us conclude that the 79 subjects (52%) who seek phalloplasty express the following requests as to their external genitalia: a scrotum (96%), a glans (92%), rigidity (86%), and an aesthetically appealing look either while wearing a tight swim suit (91%) or being nude (81%). All but 1 patient wanted to be able to void in a standing position. We add minimal disfigurement and no functional loss in the donor area as two of the goals of phalloplasty.